Mar 31, 2020

Penumbra Q1 2020 Earnings Report

Reported a revenue increase of 6.9% driven by vascular products, but neuro products declined slightly.

Key Takeaways

Penumbra, Inc. reported a 6.9% increase in revenue for the first quarter of 2020, reaching $137.3 million. The growth was primarily driven by vascular products, while neuro products experienced a slight decline. Operating income decreased compared to the previous year.

Total revenue grew to $137.3 million, a 6.9% increase over Q1 2019.

Vascular product revenue increased by 26.2%.

Neuro product revenue declined by 4.2%.

Operating income decreased to $0.6 million, compared to $11.2 million in Q1 2019.

Total Revenue
$137M
Previous year: $128M
+6.9%
EPS
$0.0392
Previous year: $0.23
-83.0%
Gross Margin
64.1%
Previous year: 65.3%
-1.8%
Gross Profit
$88M
Previous year: $83.9M
+4.9%
Cash and Equivalents
$72.5M
Previous year: $67.9M
+6.8%
Free Cash Flow
-$16.1M
Previous year: -$4.53M
+254.2%
Total Assets
$664M
Previous year: $558M
+19.1%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, Penumbra cannot, at this time, reliably estimate the future impact on our operations and financial results.

Revenue & Expenses

Visualization of income flow from segment revenue to net income